Drug activation for the discovery and development of new targeted chemotherapeutic formulations

Sotiris K. Hadjikakou
University of Ioannina, Department of Chemistry, 45110, Ioannina Greece; University Research Center of Ioannina (URCI), Institute of Materials Science and Computing, Ioannina, Greece

Conjugation of a drug with a metal is the key for its biological activity enhancement. Moreover, a new era was recently opened in the discovery and development of new therapeutic agents, from the combination of two distinct classes of chemical or biological agents into a single entity. This provides the opportunity for synergistic effects, most notably when one of the components acts as a detector agent of the targeted intracellular component, cell, tissue etc and the other interacting with the desired biological system. In our laboratory we are examining closely the biological activity of new such conjugates of drugs, metabolite, anti-metabolites, and natural product ingredients with metals aiming in the development of new chemotherapeutic agents.

Clinical trials and epidemiological studies have shown that Non-Steroidal Anti-inflammatory Drugs (NSAID’s) exhibit protective role against the incidence of mammary cancer. The conjugation of specific NSAID’s with mitochondriotropic ligands, is used for the delivery of the drugs to mitochondria as “Trojan horse”. The low toxicity against humans of silver(I) ions enables their use in the development of new metallotherapeutics.

The synthesis of a series of silver(I) metallotherapeutics of formulae \([\text{Ag(D)(EAr}_3\text{)}_n]\), (D= salicylic acid, aspirin, diclofenac, naproxen, nimesulide etc; E= P, Sb etc; Ar= Ph-, p-tolyl-, m-tolyl, o-tolyl) is reported. The compounds were characterized by spectroscopic (NMR, IR, Raman etc) and X-Ray diffraction techniques. Theses complexes were in vitro evaluated for their activity against human breast cells, MCF-7 (Hormone Depended) and MDA-MB-231 (Hormone Independent). Their toxicity was evaluated against normal human cells (normal human fetal lung fibroblast cells (MRC-5)).

Figure. Conjugation of pnictogens with NSAID in one entity

Acknowledgement: [i] This research has been co-financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE – INNOVATE (project code: T1EDK-02990) [ii] the Oncology Department of Novartis Hellas S.A.C.I. is acknowledged for the financial support (Project No. 82819). [iii] the COST Action CA17104 “New diagnostic and therapeutic tools against multidrug resistant tumors” members are thanked for the stimulating discussions